

Follow-Up After Emergency Department Visit for Substance Use (FUA)

Measure Description

The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was follow-up.

Two rates are reported:

1. The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days).
2. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).

Product Lines: Commercial, Medicaid, Medicare

Codes Included in the Current HEDIS® Measure

Description	Code
ED Visit	CPT: 99281-99285 UBREV: 0450-0452, 0456, 0459, 0981
AOD Abuse and Dependence Substance Induced Disorders	ICD-10: F10-16.xxx, F18.xxx, F19.xxx ICD-10: F10.90, F10.920-F10.99, F11.90, F11.920-F11.99, F12.90, F12.920-F12.99, F13.90, F13.920-F13.99, F14.90, F14.920-F14.99, F15.90, F15.920-F15.99, F16.90, F16.920-F16.99, F18.90, F18.920-F18.900, F19.90, F19.920-F19.99
Unintentional Drug Overdose	ICD-10: T40.xxxx-T43.xxxx, T51.xxxx
Outpatient Visit with any diagnosis of SUD, substance use, or drug overdose or with a mental health provider	CPT Visit Setting Unspecified: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875-90876, 99221-99223, 99231-99233, 99238-99239, 99252-99255 with Outpatient POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72
BH Outpatient Visit with any diagnosis of SUD, substance use, or drug overdose or with a mental health provider	CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99341, 99342, 99344, 99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015 UBREV: 0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0900, 0902-0904, 0911, 0914-0917, 0919, 0982, 0983
Partial Hospitalization or Intensive Outpatient with any diagnosis of SUD, substance use, or drug overdose or with a mental health provider	CPT Visit Setting Unspecified: 90791-90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875-90876, 99221-23, 99231-99233, 99238-99239, 99252-99255 with POS: 52 HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 UBREV: 0905, 0907, 0912, 0913
Nonresidential Substance Abuse Treatment Facility Visit with any diagnosis of SUD, substance use, or drug overdose or with a mental health provider	CPT Visit Setting Unspecified: 90791-90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875-90876, 99221-99223, 99231-99233, 99238-99239, 99252-99255 with Non-residential Substance Abuse Treatment Facility POS: 57, 58
Community Mental Health Center Visit with any diagnosis of SUD,	CPT Visit Setting Unspecified: 90791-90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875-90876, 99221-99223, 99231-99233, 99238-99239, 99252-99255 with POS: 53



substance use, or drug overdose <u>or with</u> a mental health provider	
Peer Support Service with <u>any</u> diagnosis of SUD, substance use, or drug overdose	HCPCS: G0140, G0177, H0024, H0025, H0038-H0040, H0046, H2014, H2023, S9445, T1012, T1016
Opioid Treatment Services Billed Monthly or Weekly with <u>any</u> diagnosis of SUD, substance use, or drug overdose	HCPCS OUD Monthly Office Based Treatment: G2086, G2087 HCPCS OUD Weekly Non-Drug Service: G2071, G2074-G2077, G2080
Telehealth Visit with <u>any</u> diagnosis of SUD, substance use, or drug overdose <u>or with</u> a mental health provider	CPT Visit Setting Unspecified: 90791-90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875-90876, 99221-99223, 99231-99233, 99238-99239, 99252-99255 <u>with</u> Telehealth POS: 02, 10
Telephone Visit with <u>any</u> diagnosis of SUD, substance use, or drug overdose <u>or with</u> a mental health provider	CPT: 98966-68, 99441-99443
Online Assessments (E-visit or Virtual Check-in) with <u>any</u> diagnosis of SUD, substance use, or drug overdose <u>or with</u> a mental health provider	CPT: 98970-98972, 98980-98981, 99421-99423, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250-G2252
Substance Use Disorder Services	CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012 UBREV: 0906, 0944, 0945 ICD-10 Substance Abuse Counseling and Surveillance: Z71.41, Z71.51
Behavioral Health Assessment	CPT: 99408, 99409 HCPCS: G0396, G0397, G0442, G2011, H0001, H0002, H0031, H0049
Substance Use Services	HCPCS: H0006, H0028
Medication Treatment Event	HCPCS AOD Medication Treatment: G2069, G2070, G2072, G2073, H0020, H0033, J0570-J0575, J0577, J0578, J2315, Q9991, Q9992, S0109 HCPCS OUD Weekly Drug Treatment Service: G2067-G2070, G2072, G2073

Medications

Alcohol Use Disorder Treatment Medications

Description	Prescription
Aldehyde dehydrogenase inhibitor	Disulfiram (oral)
Antagonist	Naltrexone (oral and injectable)
Other	Acamprosate (oral; delayed-release tablet)

Opioid Use Disorder Treatment Medications

Description	Prescription
Antagonist	Naltrexone (oral & injectable)
Partial agonist	Buprenorphine (sublingual tablet, injection, implant), Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film)



Ways Providers can Improve HEDIS® Performance

- Schedule follow-up visits for patients with a primary diagnosis of SUD, or any diagnosis of drug overdose, within 7 days of being seen in the ED. Telephone and/or telehealth appointments within the required timeframe meets compliance.
- Follow-up visits must be supported by a claim, encounter or note from the mental health practitioner's medical chart to count toward the measure.
- Document identified substance abuse in the member chart and submit a claim with the correct billing codes.
- Review situations where there are comorbid medical conditions. Be sure to include all diagnoses and use substance-use-related codes (ex. Cellulitis - L03.90 related to Intravenous Drug use F11.20) as these also qualify patients for the measures.

Ways Health Plans can Improve HEDIS® Performance

- Schedule follow-up visits for members with a primary diagnosis of SUD, or any diagnosis of drug overdose, within 7 days of being seen in the ED. Telephone and/or telehealth appointments within the required timeframe meets compliance.
- Refer the member to a Molina Care Manager or work collaboratively with the Molina Care Manager if one is already assigned to help increase members' access and motivation for treatment.
- Provide members with educational materials and resources that include information on the treatment processes and options, including mutual support groups and other community-based programs.
- Utilize admission, discharge, and transfer (ADT) data for early identification of discharges, if available.
- Establish value-based arrangements with behavioral health practitioners to incentivize timely follow-up visits within the required timeframe.
- Embed Health Plan staff in high-volume emergency departments to support discharge planning.

Required Exclusions

- Members who use hospice services or elect to use a hospice benefit any time during the measurement period.
- Members who die any time during the measurement year.

All summaries of the measures contained herein are reproduced with permission from HEDIS® Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA).

The information presented herein is for informational and illustrative purposes only. It is not intended, nor is it to be used, to define a standard of care or otherwise substitute for informed medical evaluation, diagnosis and treatment which can be performed by a qualified medical professional. Molina Healthcare, Inc. does not warrant or represent that the information contained herein is accurate or free from defects.

COPYRIGHT NOTICE AND DISCLAIMER

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). The HEDIS measures and specifications were developed by and are owned by NCQA. NCQA holds a copyright in these materials and may rescind or alter these materials at any time. Users of the HEDIS measures and specifications shall not have the right to alter, enhance or otherwise modify the HEDIS measures and specifications, and shall not disassemble, recompile or reverse engineer the HEDIS measures and specifications. Anyone desiring to use or reproduce the materials, subject to licensed user restrictions, without modification for an internal non-commercial purpose may do so without obtaining any approval from NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. All other uses, including a commercial use (including but not limited to vendors using the measures and specifications with a product or service to calculate measure results), or any external reproduction, distribution and publication of the HEDIS measures or results ("rates") therefrom must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program.

HEDIS measures and specifications are not clinical guidelines, do not establish a standard of medical care and have not been tested for all potential applications. The measures and specifications are provided "as is" without warranty of any kind. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of a HEDIS measure or specification. NCQA also makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on HEDIS measures and specifications or data reflective of performance under such measures and specifications.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.

CPT® codes, descriptions and other data are copyright 2024 American Medical Association (AMA). All rights reserved. CPT is a trademark of the AMA. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

Health Care Provider Taxonomy Code Set codes copyright 2024 AMA. The codes are published in cooperation with the National Uniform Claim Committee (NUCC) by the AMA. Applicable FARS/DFARS restrictions apply.

The American Hospital Association holds a copyright to the Uniform Billing Codes ("UB") contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. All uses of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.

The American Dental Association (ADA) holds a copyright to the Current Dental Terminology (CDT) codes contained in certain measure specifications. The CDT codes in the HEDIS specifications are included with the permission of the ADA. All uses of the CDT codes require a license from the ADA. No alteration, amendments, or modifications of the CDT or any portion thereof is allowed. Resale, transmission, or distribution of copies of the CDT or other portions of the CDT is also not allowed. To inquire about licensing, contact CDT-SNODENT@ada.org.

Some measure specifications contain coding from LOINC® (<https://loinc.org/>). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995–2024 Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and are available at no cost under the license at <https://loinc.org/kb/license/>.

"SNOMED" and "SNOMED CT" are registered trademarks of the International Health Terminology Standards Development Organisation (IHTSDO).

The CDC Race and Ethnicity code system was developed by the U.S. Centers for Disease Control and Prevention (CDC). NCQA's use of the code system does not imply endorsement by the CDC of NCQA, or its products or services. The code system is otherwise available on the CDC website at no charge.

Certain NullFlavor codes are owned and copyrighted by Health Level Seven International (HL7®); 2024. "HL7" is a registered trademark of Health Level Seven International.

RadLex copyright 2014, The Radiological Society of North America (RSNA), all rights reserved. Licensed under RadLex License Version 2.0. You may obtain a copy of the license at: <http://www.rsna.org/radlexdownloads/> This work is distributed under the above noted license on an "AS IS" basis, WITHOUT WARRANTIES OF ANY KIND, either express or implied. Please see the license for complete terms and conditions.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without the written permission of NCQA.

© 2024 by the National Committee for Quality Assurance
1100 13th Street NW, Third Floor,
Washington, DC 20005